Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for a clinical-stage biotech like Pluri Inc (PLUR) can run hundreds of pages, packed with scientific jargon on 3-D cell expansion, placental-derived therapies, and cultivated-meat joint ventures. Finding how much cash is left for trials, or spotting when executives file Form 4s before a financing round, is tedious.
Stock Titan solves the problem. Our AI reads every Pluri annual report 10-K, each quarterly earnings report 10-Q filing, and every 8-K material event within minutes of hitting EDGAR. It then produces plain-English summaries, highlights clinical milestones, and flags contract-development (CDMO) revenue trends so you can understand Pluri SEC documents with AI, not a microscope. You’ll also get real-time alerts on Pluri insider trading Form 4 transactions and a dashboard that links each disclosure to the exact page where the data lives.
Whether you’re monitoring a shelf registration that funds the next immunotherapy study, tracking Pluri executive stock transactions Form 4, or comparing cytokine-release safety data across periods, the entire story sits here:
- Pluri annual report 10-K simplified – R&D spend, GMP facility capacity, key risk factors
- Pluri quarterly earnings report 10-Q filing – cash runway, partnership revenue
- Pluri proxy statement executive compensation – incentive alignment for trial success
- Pluri 8-K material events explained – collaboration announcements and FDA feedback
- Pluri Form 4 insider transactions real-time – who’s buying before pivotal data
Get Pluri SEC filings explained simply, perform Pluri earnings report filing analysis in seconds, and evaluate dilution risk, cultivated-meat commercialization timelines, and more before the market digests the news. Complex filings, simplified.
Pluri Inc. (PLUR) operates a 3D cell expansion platform applied across regenerative medicine, food-tech (Ever After Foods), AgTech and a CDMO business. The company reported continued operating losses (losses of $23,250 for year ended June 30, 2025) and negative operating cash flow of $18,211, and states it must secure additional liquidity to support commercialization and R&D. Pluri completed the Kokomodo acquisition (79% for 976,139 shares), recording $2,823 of identifiable intangible assets and $3,136 of goodwill. The company has an outstanding EIB loan (linked principal and accrued interest of $27,289 presented as short-term) and is in discussions to restructure its terms. Share financings and warrant/pre-funded-warrant issuances occurred in fiscal 2025, and shareholder approval was obtained for certain warrant classifications. The company regained compliance with Nasdaq listing standards.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
